CTLA-4 Expression Plays a Role in PSC and PBC Progression

Area of Science:

• Immunogenetics
• Hepatology
• Autoimmune Diseases

Background:

• The pathogenesis of primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) is not fully understood.
• Evidence suggests the immune system plays a significant role in these cholestatic liver diseases.

Purpose of the Study:

• To investigate single nucleotide polymorphisms (SNPs) in immune regulatory genes.
• To determine if these genetic variations are associated with susceptibility or disease progression in PBC and PSC.

Main Methods:

• Genotyping of SNPs in CTLA-4, ICOS, and FOX-P3 genes in 126 patients with PBC or PSC.
• Analysis of allele variants and gene expression using RealTime PCR.
• Correlation of genetic findings with clinical data, including cirrhosis and gamma-glutamyltransferase (GGT) recovery.

Main Results:

• Lower CTLA-4 copy number was associated with cirrhosis and poorer GGT recovery in PBC/PSC patients (p=0.04).
• Two specific SNP allele variants (CTLA4 rs733618 and FOXP3 rs2280883) were linked to reduced CTLA-4 expression.
• Patients with both variants showed worsened GGT levels and a trend towards more progressive disease.

Conclusions:

• Reduced CTLA-4 expression correlates with more advanced disease in PBC and PSC.
• Identified SNP variants may predict a more severe disease course.
• These findings reinforce the involvement of immune system dysregulation in the pathogenesis of PBC and PSC.